{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:26:07Z","timestamp":1791411967010,"version":"4.3.3"},"reference-count":167,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/ajg.2016.537","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T08:02:42Z","timestamp":1484035362000},"page":"241-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":426,"title":["ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease"],"prefix":"10.14309","volume":"112","author":[{"given":"Francis A","family":"Farraye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Y","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda V","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R2-15-20210210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ibd.20266","article-title":"Receipt of preventive health services by IBD patients is significantly lower than by primary care patients.","volume":"14","author":"Selby","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R3-15-20210210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ibd.20944","article-title":"General health maintenance in IBD.","volume":"15","author":"Moscandrew","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R5-15-20210210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/17474124.2014.934672","article-title":"Vaccinating the inflammatory bowel disease patient.","volume":"9","author":"Desalermos","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R6-15-20210210","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledge.","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R7-15-20210210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ibd.21668","article-title":"Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients.","volume":"18","author":"Yeung","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R8-15-20210210","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10620-010-1329-8","article-title":"Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients?","volume":"56","author":"Selby","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R9-15-20210210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ibd.21666","article-title":"Immunizations and IBD: Whose responsibility is it? If Im the prescribing doctor, shouldnt it be mine?","volume":"18","author":"Melmed","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R10-15-20210210","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R11-15-20210210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R12-15-20210210","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","article-title":"Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake.","volume":"9","author":"Malhi","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R13-15-20210210","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ajg.2009.733","article-title":"A practical guide to vaccinating the inflammatory bowel disease patient.","volume":"105","author":"Wasan","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R14-15-20210210","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","article-title":"Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.","volume":"101","author":"Melmed","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R15-15-20210210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/00054725-200409000-00028","article-title":"Guidelines for immunizations in patients with inflammatory bowel disease.","volume":"10","author":"Sands","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R16-15-20210210","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/MIB.0000000000000395","article-title":"Immunizations in pediatric and adult patients with inflammatory bowel disease: a practical case-based approach.","volume":"21","author":"Long","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R17-15-20210210","first-page":"91","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or olderUnited States, 2015.","volume":"64","author":"Kim","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R18-15-20210210","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/M15-3005","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016.","volume":"164","author":"Kim","year":"2016","journal-title":"Ann Intern Med"},{"key":"R19-15-20210210","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1007\/s10620-016-4275-2","article-title":"Many inflammatory bowel disease patients are not immune to measles or pertussis.","volume":"61","author":"Cleveland","year":"2016","journal-title":"Dig Dis Sci"},{"key":"R20-15-20210210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.","volume":"104","author":"Loras","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R21-15-20210210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MPG.0000000000000730","article-title":"Survey of immunization practices in patients with inflammatory bowel disease among pediatric gastroenterologists.","volume":"61","author":"Lester","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R22-15-20210210","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/gut.2010.233981","article-title":"H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.","volume":"60","author":"Rahier","year":"2011","journal-title":"Gut"},{"key":"R23-15-20210210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ibd.21688","article-title":"Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.","volume":"18","author":"Dotan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R24-15-20210210","first-page":"1809","article-title":"A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.","volume":"19","author":"Parker","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R25-15-20210210","first-page":"396","article-title":"Influenza and pneumococcal vaccination rates in patients with inflammatory bowel disease.","volume":"11","author":"Reich","year":"2015","journal-title":"Gastro Hepatol"},{"key":"R26-15-20210210","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/ajg.2015.162","article-title":"Systematic information to health-care professionals about vaccination guidelines improves adherence in patients with inflammatory bowel disease in anti-TNFalpha therapy.","volume":"110","author":"Christensen","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R27-15-20210210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11894-015-0437-1","article-title":"Implementing quality measures for inflammatory bowel disease.","volume":"17","author":"Ahmed","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"R28-15-20210210","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.crohns.2014.02.022","article-title":"Improving quality of care in inflammatory bowel disease: what changes can be made today?","volume":"8","author":"Panes","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R29-15-20210210","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.14309\/00000434-201310001-01833","article-title":"The incidence of influenza and influenza-related complications in inflammatory bowel disease patients across the united states.","volume":"108","author":"Tinsley","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R30-15-20210210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CEG.S42514","article-title":"Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample.","volume":"6","author":"Stobaugh","year":"2013","journal-title":"Clin Exp Gastroenterol"},{"key":"R32-15-20210210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MIB.0000437737.68841.87","article-title":"Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement.","volume":"20","author":"Wasan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R33-15-20210210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-230X-11-87","article-title":"An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease.","volume":"11","author":"Crawford","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"R34-15-20210210","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1873-9946(12)60267-0","article-title":"Uptake in the UK of vaccination recommendations in inflammatory bowel disease (IBD).","volume":"6","author":"Burger","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R35-15-20210210","doi-asserted-by":"crossref","first-page":"A234","DOI":"10.1136\/gutjnl-2012-302514c.121","article-title":"Compliance with guidelines on viral screening and vaccination of patients with inflammatory bowel disease (IBD).","volume":"61","author":"Halliday","year":"2012","journal-title":"Gut"},{"key":"R36-15-20210210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.crohns.2011.12.013","article-title":"Adherence of gastroenterologists to European Crohns and Colitis Organisation consensus on Crohns disease: a real-life survey in Spain.","volume":"6","author":"Hinojosa","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R37-15-20210210","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S1590-8658(13)60257-1","article-title":"Vaccination status in inflammatory bowel disease patients.","volume":"45","author":"Morace","year":"2013","journal-title":"Dig Liver Dis"},{"key":"R38-15-20210210","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S1873-9946(14)60421-9","article-title":"Vaccination routines during anti-TNF treatment in IBD: Do patients adhere to ECCOs guidelines?","volume":"8","author":"Risager Christensen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R39-15-20210210","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/S1873-9946(14)60688-7","article-title":"Adherence to quality measures for inflammatory bowel disease in Korea: questionnaire study based on American Gastroenterological Association Adult Inflammatory Bowel Disease Physician Performance Measures Set.","volume":"8","author":"Song","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R40-15-20210210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3109\/00365521.2011.574734","article-title":"The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.","volume":"46","author":"Wilckens","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"R41-15-20210210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5009\/gnl.2014.8.3.242","article-title":"Insufficient knowledge of korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease.","volume":"8","author":"Jung","year":"2014","journal-title":"Gut Liver"},{"key":"R42-15-20210210","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2011.11.109","article-title":"Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review.","volume":"30","author":"Agarwal","year":"2012","journal-title":"Vaccine"},{"key":"R43-15-20210210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","article-title":"Immune response to influenza AH1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants.","volume":"7","author":"Andrisani","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R44-15-20210210","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R45-15-20210210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.crohns.2013.08.008","article-title":"Infliximab andor immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease.","volume":"8","author":"Hagihara","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R46-15-20210210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2008.120","article-title":"Immune response to influenza vaccine in children with inflammatory bowel disease.","volume":"104","author":"Lu","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R47-15-20210210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cgh.2007.02.035","article-title":"Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.","volume":"5","author":"Mamula","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R48-15-20210210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ibd.21706","article-title":"JC, Hilsden R, Fonseca K et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R49-15-20210210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gutjnl-2011-300256","article-title":"Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.","volume":"61","author":"Cullen","year":"2012","journal-title":"Gut"},{"key":"R50-15-20210210","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s10620-015-3631-y","article-title":"Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis.","volume":"60","author":"Nguyen","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R51-15-20210210","first-page":"638","article-title":"J, Fonseca K, Ghosh S et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial.","volume":"22","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R52-15-20210210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ajg.2011.320","article-title":"Vaccinations while on thiopurines: some protection is better than none.","volume":"107","author":"Melmed","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R53-15-20210210","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/ibd.20943","article-title":"Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.","volume":"15","author":"Melmed","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R57-15-20210210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R58-15-20210210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MPG.0b013e31825959b8","article-title":"Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.","volume":"55","author":"Rufo","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R59-15-20210210","first-page":"41","article-title":"Prevention of opportunistic infections in patients with inflammatory bowel disease and implications of the ECCO consensus in Belgium.","volume":"73","author":"Rahier","year":"2010","journal-title":"Acta Gastroenterol Belg"},{"key":"R60-15-20210210","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/mib.0b013e31828278a2","article-title":"Quality indicators for inflammatory bowel disease: development of process and outcome measures.","volume":"19","author":"Melmed","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R61-15-20210210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/ajg.2012.406","article-title":"Increased risk of pneumonia among patients with inflammatory bowel disease.","volume":"108","author":"Long","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R62-15-20210210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.crohns.2012.02.015","article-title":"Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases.","volume":"7","author":"Ananthakrishnan","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R63-15-20210210","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a Nationwide Danish Cohort Study 1977-2013.","volume":"110","author":"Kantso","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R64-15-20210210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ajg.2009.523","article-title":"Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease.","volume":"105","author":"Melmed","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R65-15-20210210","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study.","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R66-15-20210210","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/MIB.0000000000000406","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease.","volume":"21","author":"Banaszkiewicz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R67-15-20210210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster.","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"R69-15-20210210","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/ibd.22950","article-title":"Varicella zoster virus infection in inflammatory bowel disease.","volume":"18","author":"Cullen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R70-15-20210210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ijcp.12508","article-title":"Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study.","volume":"69","author":"Tsai","year":"2015","journal-title":"Int J Clin Pract"},{"key":"R71-15-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R72-15-20210210","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R73-15-20210210","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine.","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R74-15-20210210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"R75-15-20210210","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"R76-15-20210210","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMe1505050","article-title":"A new vaccine to prevent herpes zoster.","volume":"372","author":"Cohen","year":"2015","journal-title":"N Engl J Med"},{"key":"R77-15-20210210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPG.0b013e31821e1917","article-title":"Varicella immunity in inflammatory bowel disease.","volume":"53","author":"Ansari","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R78-15-20210210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2036.2012.05150.x","article-title":"Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines.","volume":"36","author":"Kopylov","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R80-15-20210210","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MPG.0b013e3181bab351","article-title":"Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy.","volume":"50","author":"Lu","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R81-15-20210210","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.idc.2012.06.003","article-title":"The immunosuppressed traveler.","volume":"26","author":"Visser","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"R82-15-20210210","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R83-15-20210210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MEG.0000000000000280","article-title":"Mulak A et al. cocoon immunization strategy among patients with inflammatory bowel disease.","volume":"27","author":"Waszczuk","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R84-15-20210210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"R85-15-20210210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1620\/tjem.229.29","article-title":"Influenza vaccination in autoimmune rheumatic disease patients.","volume":"229","author":"Milanovic","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R86-15-20210210","first-page":"13","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R87-15-20210210","first-page":"1","article-title":"General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"60","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"R88-15-20210210","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"R89-15-20210210","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0149-2918(01)80044-8","article-title":"Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines.","volume":"23","author":"Coates","year":"2001","journal-title":"Clin Ther"},{"key":"R90-15-20210210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrgastro.2013.28","article-title":"Vaccination strategies in patients with IBD.","volume":"10","author":"Gisbert","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R91-15-20210210","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease.","volume":"21","author":"Marin","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R92-15-20210210","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2036.2012.05110.x","article-title":"Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R93-15-20210210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.vaccine.2009.10.110","article-title":"Hepatitis B vaccines: WHO position paperrecommendations.","volume":"28","author":"Publication","year":"2010","journal-title":"Vaccine"},{"key":"R94-15-20210210","first-page":"561","article-title":"B immunity? European Consensus Group on Hepatitis B Immunity.","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R95-15-20210210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"R97-15-20210210","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000001263","article-title":"157: Cervical Cancer Screening and Prevention.","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R98-15-20210210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cgh.2008.10.007","article-title":"Suboptimal rates of cervical testing among women with inflammatory bowel disease.","volume":"7","author":"Long","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R99-15-20210210","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ibd.21567","article-title":"Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study.","volume":"17","author":"Singh","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R100-15-20210210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","article-title":"Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R101-15-20210210","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasiacancer? A meta-analysis.","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R103-15-20210210","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases.","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R104-15-20210210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.PSY.0000106907.24881.F2","article-title":"Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.","volume":"66","author":"Mittermaier","year":"2004","journal-title":"Psychosom Med"},{"key":"R105-15-20210210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2036.2005.02535.x","article-title":"The impact of major depressive disorder on the short- and long-term outcome of Crohns disease treatment with infliximab.","volume":"22","author":"Persoons","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R106-15-20210210","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00054725-200608000-00004","article-title":"Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohns disease.","volume":"12","author":"Calvet","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R107-15-20210210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1751-0759-2-11","article-title":"Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective study.","volume":"2","author":"Mikocka-Walus","year":"2008","journal-title":"Biopsychosoc Med"},{"key":"R108-15-20210210","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gut.2007.134817","article-title":"Predicting relapse in Crohns disease: a biopsychosocial model.","volume":"57","author":"Bitton","year":"2008","journal-title":"Gut"},{"key":"R109-15-20210210","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/ajg.2012.471","article-title":"Similar risk of depression and anxiety following surgery or hospitalization for Crohns disease and ulcerative colitis.","volume":"108","author":"Ananthakrishnan","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R110-15-20210210","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1097\/MIB.0b013e3182a192ba","article-title":"Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study.","volume":"19","author":"Langhorst","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R111-15-20210210","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1053\/j.gastro.2006.05.017","article-title":"The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis.","volume":"131","author":"Mawdsley","year":"2006","journal-title":"Gastroenterology"},{"key":"R112-15-20210210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1745-0179-2-24","article-title":"Antidepressants and inflammatory bowel disease: a systematic review.","volume":"2","author":"Mikocka-Walus","year":"2006","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"R113-15-20210210","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ibd.22916","article-title":"Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.","volume":"18","author":"Goodhand","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R114-15-20210210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jpsychores.2011.06.006","article-title":"The role of antidepressants in the management of inflammatory bowel disease (IBD): a short report on a clinical case-note audit.","volume":"72","author":"Mikocka-Walus","year":"2012","journal-title":"J Psychosom Res"},{"key":"R115-15-20210210","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00004836-200101000-00015","article-title":"Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance.","volume":"32","author":"Nigro","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"R116-15-20210210","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1572-0241.2007.01212.x","article-title":"Predictors of medication adherence in inflammatory bowel disease.","volume":"102","author":"Ediger","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R117-15-20210210","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0022-3999(03)00122-3","article-title":"Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohns disease: main results of the German Prospective Multicenter Psychotherapy Treatment study on Crohns Disease.","volume":"56","author":"Keller","year":"2004","journal-title":"J Psychosom Res"},{"key":"R118-15-20210210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ibd.20068","article-title":"Psychological treatment may reduce the need for healthcare in patients with Crohns disease.","volume":"13","author":"Deter","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R122-15-20210210","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaad.2005.08.065","article-title":"Presentation and detection of invasive melanoma in a high-risk population.","volume":"54","author":"McPherson","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R123-15-20210210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3322\/caac.20074","article-title":"The evolution of melanoma diagnosis: 25 years beyond the ABCDs.","volume":"60","author":"Rigel","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R124-15-20210210","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/MIB.0b013e3182802c07","article-title":"Skin side effects of inflammatory bowel disease therapy.","volume":"19","author":"Torres","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R125-15-20210210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R126-15-20210210","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007890-199003000-00006","article-title":"Incidence of skin cancer after renal transplantation in The Netherlands.","volume":"49","author":"Hartevelt","year":"1990","journal-title":"Transplantation"},{"key":"R128-15-20210210","first-page":"586","article-title":"Squamous and basal cell carcinoma in heart transplant recipients.","volume":"17","author":"Lampros","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"R130-15-20210210","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djs529","article-title":"HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer.","volume":"105","author":"Silverberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R131-15-20210210","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archderm.140.9.1079","article-title":"Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.","volume":"140","author":"Fortina","year":"2004","journal-title":"Arch Dermatol"},{"key":"R132-15-20210210","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.tp.0000269707.06060.dc","article-title":"Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients.","volume":"84","author":"Ramsay","year":"2007","journal-title":"Transplantation"},{"key":"R133-15-20210210","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/archdermatol.2009.276","article-title":"Incidence of and risk factors for skin cancer after heart transplant.","volume":"145","author":"Brewer","year":"2009","journal-title":"Arch Dermatol"},{"key":"R135-15-20210210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkins lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"key":"R136-15-20210210","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R137-15-20210210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1345\/aph.1H219","article-title":"Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.","volume":"41","author":"Masunaga","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R138-15-20210210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R139-15-20210210","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/1097-0142(19910401)67:7<2015::AID-CNCR2820670731>3.0.CO;2-R","article-title":"Extracolonic malignancies in inflammatory bowel disease.","volume":"67","author":"Ekbom","year":"1991","journal-title":"Cancer"},{"key":"R140-15-20210210","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"R141-15-20210210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2036.2004.01858.x","article-title":"Intestinal and extra-intestinal cancer in Crohns disease: follow-up of a population-based cohort in Copenhagen County, Denmark.","volume":"19","author":"Jess","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R142-15-20210210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R143-15-20210210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ijc.2910600309","article-title":"Cancer in patients with ulcerative colitis.","volume":"60","author":"Mellemkjaer","year":"1995","journal-title":"Int J Cancer"},{"key":"R144-15-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R146-15-20210210","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"R147-15-20210210","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/gut.2009.181982","article-title":"Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.","volume":"58","author":"Sokol","year":"2009","journal-title":"Gut"},{"key":"R148-15-20210210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R149-15-20210210","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/ajg.2014.298","article-title":"et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.","volume":"109","author":"Abbas","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R150-15-20210210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0016-5085(95)90068-3","article-title":"Metabolic bone assessment in patients with inflammatory bowel disease.","volume":"108","author":"Abitbol","year":"1995","journal-title":"Gastroenterology"},{"key":"R151-15-20210210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","article-title":"AGA technical review on osteoporosis in gastrointestinal diseases.","volume":"124","author":"Bernstein","year":"2003","journal-title":"Gastroenterology"},{"key":"R152-15-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1572-0241.1998.468_q.x","article-title":"Femoral neck osteopenia in patients with inflammatory bowel disease.","volume":"93","author":"Pollak","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R153-15-20210210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjmed.2009.01.022","article-title":"Osteoporosis in inflammatory bowel disease.","volume":"122","author":"Ali","year":"2009","journal-title":"Am J Med"},{"key":"R154-15-20210210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00042737-200308000-00003","article-title":"Bone loss associated with gastrointestinal disease: prevalence and pathogenesis.","volume":"15","author":"Vestergaard","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R155-15-20210210","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/gast.2002.34779","article-title":", Crowson CS, Sandborn WJ et al. Long-term fracture risk in patients with Crohns disease: a population-based study in Olmsted County, Minnesota.","volume":"123","author":"Loftus","year":"2002","journal-title":"Gastroenterology"},{"key":"R156-15-20210210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2012.10.022","article-title":"Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis.","volume":"11","author":"Targownik","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R157-15-20210210","first-page":"469","article-title":"Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease.","volume":"95","author":"Vestergaard","year":"2004","journal-title":"Minerva Med"},{"key":"R158-15-20210210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/gut.46.2.176","article-title":"Fracture risk is increased in Crohns disease, but not in ulcerative colitis.","volume":"46","author":"Vestergaard","year":"2000","journal-title":"Gut"},{"key":"R159-15-20210210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.2003.026799","article-title":"Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study.","volume":"53","author":"Card","year":"2004","journal-title":"Gut"},{"key":"R160-15-20210210","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R161-15-20210210","first-page":"639","article-title":"Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis.","volume":"104","author":"Shen","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R162-15-20210210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","article-title":"Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.","volume":"62","author":"Compston","year":"2009","journal-title":"Maturitas"},{"key":"R163-15-20210210","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.","volume":"182","author":"Papaioannou","year":"2010","journal-title":"CMAJ"},{"key":"R165-15-20210210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom.","volume":"93","author":"van Staa","year":"2000","journal-title":"QJM"},{"key":"R166-15-20210210","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/bmj.289.6450.954","article-title":"Smoking and Crohns disease.","volume":"289","author":"Somerville","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R167-15-20210210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1440-1746.2009.06140.x","article-title":"Population-based cases control study of inflammatory bowel disease risk factors.","volume":"25","author":"Gearry","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R168-15-20210210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.292.6528.1101","article-title":"Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age.","volume":"292","author":"Vessey","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R169-15-20210210","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.mib.0000228998.29466.ac","article-title":"Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population.","volume":"12","author":"Halfvarson","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"R170-15-20210210","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4065\/81.11.1462","article-title":"Smoking and inflammatory bowel disease: a meta-analysis.","volume":"81","author":"Mahid","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R171-15-20210210","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/MIB.0b013e3182802b3e","article-title":"Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort.","volume":"19","author":"Lakatos","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R172-15-20210210","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/apt.12440","article-title":"Smoking does influence disease behaviour and impacts the need for therapy in Crohns disease in the biologic era.","volume":"38","author":"Nunes","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R173-15-20210210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ibd.22959","article-title":"Does smoking influence Crohns disease in the biologic era? The TABACROHN study.","volume":"19","author":"Nunes","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R174-15-20210210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/apt.13511","article-title":"Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohns disease.","volume":"43","author":"To","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R175-15-20210210","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohns disease.","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"R176-15-20210210","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohns disease.","volume":"17","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R177-15-20210210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ibd.21456","article-title":"Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease.","volume":"17","author":"Domenech","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R178-15-20210210","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/apt.12176","article-title":"Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohns disease.","volume":"37","author":"Gustavsson","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R179-15-20210210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjsurg.2003.11.007","article-title":"Crohns disease patients who quit smoking have a reduced risk of reoperation for recurrence.","volume":"187","author":"Ryan","year":"2004","journal-title":"Am J Surg"},{"key":"R180-15-20210210","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1053\/gast.2001.23231","article-title":"Smoking cessation and the course of Crohns disease: an intervention study.","volume":"120","author":"Cosnes","year":"2001","journal-title":"Gastroenterology"},{"key":"R181-15-20210210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00418-011-0902-3","article-title":"Cigarette smoke and the terminal ileum: increased autophagy in murine follicle-associated epithelium and Peyers patches.","volume":"137","author":"Verschuere","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"R182-15-20210210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/jgh.12674","article-title":"Smoking behaviour modifies IL23r-associated disease risk in patients with Crohns disease.","volume":"30","author":"Doecke","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R183-15-20210210","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/ibd.21889","article-title":"Current smoking differentially affects blood mononuclear cells from patients with Crohns disease and ulcerative colitis: relevance to its adverse role in the disease.","volume":"18","author":"Bergeron","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R184-15-20210210","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ibd.21864","article-title":"Smokers with active Crohns disease have a clinically relevant dysbiosis of the gastrointestinal microbiota.","volume":"18","author":"Benjamin","year":"2012","journal-title":"Inflamm Bowel Dis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016537","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201702000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:15:02Z","timestamp":1786547702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201702000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":167,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.537","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}